Skip to main content
PLOS Global Public Health logoLink to PLOS Global Public Health
. 2025 Apr 8;5(4):e0004420. doi: 10.1371/journal.pgph.0004420

Driving under viral impairment: Linking acute SARS-CoV-2 infections to elevated car crash risks

Baran Erdik 1,2,*
Editor: Jose Ignacio Nazif-Munoz3
PMCID: PMC11978055  PMID: 40198595

Abstract

This study explores the linkage between acute SARS-CoV-2 and car crashes across U.S. states, correlating with COVID-19 mitigation strategies, vaccination rates, and Long COVID prevalence. This investigation analyzed aggregate COVID-19 and car crash data spanning 2020–2023, with data collection occurring between March and May 2024. Analysis was done via a Poisson regression model, adjusted for population. Key variables included vaccination status, month-specific effects relating to initial pandemic shutdowns, and Long COVID rates. Results demonstrated a significant association between acute COVID-19 infections and an increase in car crashes, independent of Long COVID status to the tune of an OR of 1.25 [1.23-1.26]. This association was observed despite varying mitigation efforts and vaccination rates across states. The study found no protective effect of vaccination against car crashes, challenging prior assumptions about the benefits of vaccination. Notably, the risk associated with COVID-19 was found to be analogous to driving impairments seen with alcohol consumption at legal limits. Findings suggest significant implications for public health policies, especially in assessing the readiness of individuals recovering from COVID-19 to engage in high-risk activities such as pilots or nuclear plant employees. Further research is necessary to establish causation and explore the exact effects of COVID-19 within the CNS affecting cognition and behavior.

Introduction

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first reported in December 2019. Since then, it has resulted in over one million deaths in the US alone as well as an estimated incidence of almost 3.5 infections per person as of early 2024 [1]. Beyond acute hospitalizations and associated mortality and morbidity, one of the main concerns surrounding COVID-19 is the post-COVID-19 conditions termed long COVID or post-acute sequelae of SARS-CoV-2 infection (PASC) which affect at least a quarter of patients or more surviving even mild cases of COVID. A recent longitudinal follow-up study demonstrated that almost 63% of those who have had COVID-19 met the criteria for long-term COVID [2,3].

Studies in this context have demonstrated that Long Covid is associated with numerous symptoms affecting all bodily systems and can be clustered within categories. One of the main symptom clusters is cognitive complaints, particularly memory and concentration deficits with data indicating more than 30% of those that have had acute COVID-19 reporting such symptoms [4]. Further, it has been shown that reinfections confer increased risk of Long Covid, and the data demonstrating protective effect of vaccination on Long Covid is conflicting [5,6]. In light of such data, as well as removal of all mitigation efforts in the US, the question of Long Covid evolves into a matter of when, not if [7,8].

Several hypotheses have been proposed regarding Long Covid, mainly viral persistence, immune dysregulation, and viral reactivation [9]. From a neuropathological perspective, it has been shown that immune dysregulation within the immune system is evident with persistent immune activation in the context of antibody secreting B cells [10], microglial activation associated with poor cognitive function [11,12], as well as effects of SARS-CoV-2 on the microvasculature, which can explain pan-cerebral issues along with perturbations of synaptic function in general [13,14]. Further, it’s also been shown that macrophages can enter the brain tissue post COVID-19, and stay in perpetuity leading to neural inflammation [15,16]. Not surprisingly, studies have also demonstrated loss of brain volume, increased risk of Alzheimer’s and numerous autonomic nervous system issues as postural tachycardia syndrome (POTS), some with sufficient severity that it may lead to Ondine’s curse [1719]. Additionally, neural viral reservoirs may perpetuate immune dysregulation, culminating in T-cell exhaustion [20,21]. Regardless of the pathogenesis, the phenomenon commonly referred to as “brain fog,” characterized primarily by cognitive impairments, is becoming increasingly prevalent. Data indicate that even mild acute infections can have lasting effects on brain function, potentially leading to significant challenges in tasks that demand high levels of attention and cognitive processing [22].

One such cognitively demanding task is driving, which relies heavily on psychomotor speed, executive function, and visual processing [23,24]. It is well established that impairments in these domains, as seen in conditions such as ADHD and dementia, correlate with an increased risk of motor vehicle crashes. Despite this, most states do not require specific medical evaluations or tests to obtain a driver’s license, with a few exceptions for conditions like epilepsy or for older adults [2527]. Given the effects of Long COVID and the sheer scale of numbers affected, the full impact of COVID-19 on driving remains largely unknown. In this sense, studies have analyzed increases in car crashes as well as crash mortality in the US contemporarily with COVID-19 pandemic [28] While these analyses did not directly attribute these increases to COVID-19 beyond government-imposed “stay-at-home” orders -shutdowns-, they may have correctly identified a trend without recognizing the role of SARS-CoV-2 as a contributing factor. The virus has been shown to increase aggression, impair visuoconstructional abilities, and induce cognitive dysfunction—factors that collectively elevate the risk of automobile crashes [29,30].

Initial studies during the pandemic consistently documented a reduction in car crash rates during the early stages of the pandemic [31]. These decreases were mainly observed in less severe collisions occurring during rush hour or in minor-moderate crashes that were not fatal but would require hospitalization [3236]. Conversely, fatal crashes increased, largely attributed to speeding and reduced traffic volume [37,38].

Beyond speeding, factors such as reckless driving, inattentiveness, and aggression have also been implicated in the rise of severe crashes, although no direct links to SARS-CoV-2’s effects on the central nervous system (CNS) have been proposed [28]. Further, studies in numerous states have repeated these findings, associating increases risk-taking behaviors such as failure to use a seatbelt with increases in fatality and severity of crashes. In the same sense, studies have also demonstrated that SARS-CoV-2 vaccine hesitancy was associated car crashes and severity, indicating that inherent risk hesitancy and associated risk taking maybe exacerbated by SARS-CoV-2 [29,30,34,39].

Further complicating the picture, while the total number of crashes decreased, fatal crashes increased due to single-vehicle crashes, often attributed to risk-taking behavior [40]. Demonstrating the possible neurophysiological role of SARS-CoV-2 as the main driver of increases in severe and fatal crashes, studies have shown increased risk-taking behavior in recovered COVID-19 patients, possibly due to ongoing damage to the limbic system, mainly the amygdala [4144]. While some researchers have argued that such risk taking maybe secondary to boredom and direct effects of the pandemic mitigation efforts, this explanation fails to account for global patterns observed across diverse cultural contexts and varying levels of pandemic restrictions [45]. The changes in car crash composition and risk-taking behavior were demonstrated to be a global phenomenon, strengthening our hypothesis that the CNS related changes owing to SARS-CoV-2 are to blame [46,47].

Moreover, although some states suspended on-the-road testing for teenage drivers during the early pandemic, the outcomes did not significantly deviate from the norm, as most states do not require behind-the-wheel training. While young and newly licensed drivers typically have higher crash rates, these incidents are usually non-fatal [4850]. Lower socioeconomic status (SES) remains a significant factor in road safety and risk-taking behavior within this demographic, reinforcing the link between SES and increased risk. Internationally, similar changes in driving behavior have been observed, such as in Greece and Saudi Arabia, where speeding and fatal crash rates increased despite robust pandemic mitigation efforts, further challenging the notion that these trends result solely from mitigation measures like stay-at-home orders [51,52]. The demographic and psychological profiles of individuals who defied pandemic mitigation measures may offer additional insights into these patterns. Such individuals—often characterized by lower SES, educational attainment, employment in the service industry, ownership of older or less safe vehicles, younger age, male gender, and a history of substance abuse—were more likely to be on the road during stay-at-home orders, increasing their exposure to SARS-CoV-2 and, consequently, their likelihood of subsequent reinfections [5356]. Supporting this perspective, data suggest that drivers self-reported engaging in fewer risky behaviors during the pandemic [57]. However, international data, such as from Thailand, where a second stay-at-home order following a surge in COVID-19 cases resulted in an increase in crashes and fatalities, contradicts the notion that mitigation efforts alone can account for these changes [58] Additionally, the rise in motorcycle crashes and non-compliance with safety measures globally suggests a broader shift in risk-taking behavior, potentially linked to the neurophysiological effects of SARS-CoV-2 [59].

Materials & methods

Study design

In response to the growing SARS-CoV-2 and Long COVID-19 epidemic, we conducted an in-depth analysis of the correlation between acute COVID-19 cases and the incidence of car crashes across seven states. This analysis was stratified by SARS-CoV-2 vaccination rates, Long COVID-19 prevalence as reported by the Centers for Disease Control and Prevention (CDC), and early pandemic policies, specifically in states with minimal or no COVID-19 restrictions [60].

Data collection

Data collection spanned March to May 2024, covering data from 2020 to 2023 to ensure finalization and completeness. To ensure robust findings, we amalgamated car crash data from each state’s Department of Transportation (DOT) or equivalent, cross-referencing with the National Highway Traffic Safety Administration (NHTSA) data repository to ensure accuracy and consistency. Specifically, crash data were obtained from the following sources: the TxDOT Crash Query Tool (C.R.I.S. Query) for Texas, the MassDOT IMPACT tool for Massachusetts, the Washington State Collision Analysis Tool for Washington State, the Iowa DOT ICAT for Iowa, the Connecticut Crash Data Repository for Connecticut, the Florida Highway Safety and Motor Vehicles (FLHSMV) Crash Dashboard for Florida, and the GDOT Crash Data Portal for Georgia [6168]. This multi-source approach ensured that discrepancies or incomplete data from one repository could be cross-verified and resolved.

COVID-19 vaccination data were sourced from the CDC’s National Center for Immunization and Respiratory Diseases (NCIRD) [69]. Given the inherent variability in test reporting and the widespread use of at-home antigen testing—results of which are largely unreported—we employed PCR positivity rates obtained from the U.S. Department of Health & Human Services/ Centers for Disease Control and Prevention (CDC) as a surrogate marker for COVID-19 incidence [70]. PCR positivity rates were validated using time-series data from the Pandemic Mitigation Collaborative (PMC) and wastewater SARS-CoV-2 RNA levels from the CDC [1,70,71]. Refined wastewater metrics, accounting for population size, wastewater flow rates, and environmental conditions, showed strong positive correlations with PCR positivity rates (R² > 0.92, p < 0.001), with validation performed via regression analysis. These validations confirm PCR positivity as a reliable proxy for COVID-19 case numbers in line with previous literature [72] not only validating PCR positivity rates as a reliable measure of COVID-19 incidence but also underscoring the utility of such in epidemiological analyses, particularly when traditional testing data may be incomplete or biased.

Statistical reasoning

The Poisson regression model was used to assess the relationship between acute COVID-19 incidence and car crashes. Fixed effects were applied to control for state-specific characteristics, as the analysis focused on state-level data. State-level fixed effects accounted for differences in policy implementation, population density, and road usage patterns. Overdispersion was evaluated using the Pearson dispersion statistic. The absence of significant overdispersion justified the use of the Poisson model over a Negative Binomial alternative.

The log of the population was included as an offset in the Poisson regression equation to account for differences in population size among states. The outcome variable, the count of car crashes, was modeled as a log-transformed variable. Covariates included vaccination rates, Long COVID-19 prevalence, and PCR positivity rates. Interaction terms between mitigation measures and vaccination rates were considered but ultimately excluded due to lack of statistical significance and lack of available enforcement/compliance data. Descriptive statistics for all datasets are detailed in Table 1.

Table 1. Descriptive Statistics.

Parameter Car Crash Rate, Mean ± STD, (Range) P Value
OVERALL 20.9 ± 8.1, (6.3 - 42)
YEAR 0.0057
2020 18.3 ± 7.4, (6.3 – 38.1)
2021 21.9 ± 8.4, (9.1 – 42.0)
2022 22.0 ± 8.0, (9.5 – 40.3)
STATE <.0001
CT 28.5 ± 5.0, (12.5 – 36.6)
FL 16.5 ± 1.9, (9.1 – 18.7)
GA 33.9 ± 4.9, (16.9 – 42.0)
IA 11.4 ± 2.0, (6.3 – 15.9)
MA 19.3 ± 3.5, (8.7 – 24.9)
TX 21.9 ± 2.6, (12.8 – 25.9)
WA 14.6 ± 2.3, (7.4 – 19.0)

Range was defined as minimum through maximum.

P values indicated the statistically significant difference at 95% confidence interval, which was calculated from ANOVA test.

Correlation analysis and heat map

A correlation analysis was conducted to assess whether changes in one variable were associated with changes in another. Highly correlated variables (above 0.75) were excluded from the multivariable model to avoid collinearity. Pearson’s correlation coefficient was used to quantify the strength and direction of associations. To visualize correlations, a heat map was constructed, categorizing correlations as high (above 0.75), medium (0.5–0.75), or low (below 0.5). The heat map revealed no significant correlations among predictor variables, validating the independence of variables used in the Poisson regression model (Fig 1). The heat map also informed variable selection by excluding predictors with potential collinearity, thereby improving the robustness of the regression model.

Fig 1. Correlation Heat Map.

Fig 1

Software

All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC). No custom scripts or extensions were applied to the software during the analysis.

Supplementary data

The complete dataset is available in S1 and S2 Data. S1 Data (Wastewater Data) includes three tabs: percentage subsets of wastewater metrics, concentration data, and a master list of facilities. S2 Data provides the remaining datasets. Changes in facility names, primarily within the Verily-sourced wastewater data, are noted.

Statistical analysis

The 2020–2022 data were fitted to a Poisson regression model. The log of population (per the US Census) was an offset variable for differences among seven states (Connecticut, Florida, Georgia, Iowa, Massachusetts, Texas, and Washington). (Table 2) Binary variables for March, April, and May were included separately because those were the months of the shutdowns in most US states and were included in the model that found no correlation between car crashes and concurrent COVID-19 rate (% positive PCR). The form of the equation with log-transformation was: log(μi) = β0 + β1 (COVID-19 rate) + β2 (vaccination rate) + β3 (March) + β4 (April) + β5 (May) + log(populationi), Where: μi represents the expected number of car crashes in state i; log(populationi) is included as an offset to account for population differences.

Table 2. State Characteristics.

Connecticut (CT) Florida (FL) Georgia (GA) Iowa (IA) Massachusetts (MA) Texas (TX) Washington (WA)
Long Covid Rate Per CDC (early 2024) (60) 5.2% 5.9% 6.2% 7.1% 5.3% 6.5% 5.2%
Timing of Stay-at-Home Orders 03/23/20-05/20/20 04/02/20-05/04/20 04/02/20-04/30/20 None 03/24/20-05/18/20 04/02/20-04/30/20 03/24/20-05/31/20
Duration of Mask Mandates 683 Days None None 82 Days 388 Days 250 Days 625 Days
Cumulative Adult (18+) Initial COVID-19 Vaccination Completion Rate on 12/30/21 74.6% 63.4% 51% 59% 74.6% 57.7% 68.6%

A Poisson regression model was chosen for its effectiveness in modeling count data, particularly for rare events like car crashes, where the data is characterized by rare occurrences and skewed distributions, as supported by prior literature [25,37]. Fixed effects were used in the model to account for specific state-level differences, given the focus on evaluating how various state policies, mitigation efforts, and vaccination rates influenced crash rates to control for observed, non-random variability across states while ensuring the model’s estimates were not biased by unobserved heterogeneity. This approach was appropriate given the study’s focus on state-specific impacts of SARS-CoV-2 incidence and policy rather than broader variation across states, which would have warranted random effects. The log of the population was included as an offset variable to adjust for differing population sizes across states. Overdispersion, a common issue in count data where variance exceeds the mean, was assessed using the dispersion statistic (ratio of the deviance to the degrees of freedom), being critical in ensuring the model’s robustness and accuracy, as overdispersion can lead to underestimation of standard errors, resulting in misleading inferences. In our model, overdispersion was specifically assessed by comparing the variance and mean of the outcome variable, with the dispersion statistic (ratio of the deviance to the degrees of freedom) suggesting minimal overdispersion (value close to 1), indicating that the Poisson model appropriately fits the data without underestimating standard errors. Consequently, a negative binomial model, typically used for significant overdispersion, was deemed unnecessary due to the observed minor overdispersion. Ultimately, Poisson regression is well-suited to situations requiring adjustments for varying population sizes across different States, thus allowing for a more nuanced analysis of the incidence rate of car crashes as a function of predictor variables. By incorporating variables such as COVID-19 infection rates alongside other relevant covariates, Poisson regression has in this context facilitated a robust framework for analyzing the relationship between SARS-CoV-2 and road safety outcomes while accounting for state-level population differences and other contextual factors.

Results

The increases in crash frequency temporally coincided with the initial dip in SARS-CoV-2 rates thanks to stay-at-home orders, and subsequently ever increased following removal of most mitigations and advent of ever-virulent variants, e.g., Delta and Omicron. Not surprisingly, our data demonstrate lower COVID-19 rates in states with more stringent mitigation efforts, namely masking mandates and higher vaccination rates. (Tables 2 and 3) As discussed above, to evaluate the relationship between variables, the correlation analysis conducted visually summarizes the correlations in a heat map (Fig 1), categorizing them as high (>0.75), medium (0.5–0.75), or low (<0.5). The heat map (Fig 1) revealed no significant correlations among predictor variables, validating their independence and inclusion in the Poisson regression model. Ultimately, our analysis demonstrated that acute COVID as measured by PCR positivity was associated with an odds ratio (OR) of 1.25 (1.23-1.26 95%CI) for subsequent car crashes indicating a 25% increase in crash risk associated with acute COVID-19. (Table 3). The results were consistent across univariate and multivariate analyses, demonstrating statistically significant results (p<0.05) in all states except Iowa and Washington. (Table 3)

Table 3. Univariable and Multivariable Analysis on Car Crashes by COVID-19 Rate through Poisson Regression Model.

PARAMETER OR (95% CI) P Value a
Univariate Model
% Positive PCRs 1.25 [1.23 - 1.26] <.0001
Multivariate Model
% Positive PCRs 1.44 [1.42 - 1.47] <.0001
Vaccination 0.98 [0.97 - 0.98] <.0001
March 1.04 [1.04 - 1.05] <.0001
April 1.05 [1.05 - 1.06] <.0001
May 0.99 [0.99 - 0.99] <.0001
Stratified by State
STATE OR (95% CI) P Value a
CT 3.19 [2.99 - 3.41] <.0001
FL 1.37 [1.33 - 1.42] <.0001
GA 1.65 [1.60 - 1.70] <.0001
IA 1.10 [0.99 - 1.22] 0.0687
MA 5.22 [4.88 - 5.58] <.0001
TX 1.30 [1.27 - 1.32] <.0001
WA 1.02 [0.95 - 1.10] 0.5608

aBolded P value indicated statistical significance within a 95% confidence interval, i.e., P<0.05.

Discussion

Previous studies utilizing similar Poisson regression has demonstrated a connection between the number of accumulated COVID-19 cases and an increase in road fatalities, but not simultaneously and in a temporally associated manner [73]. Our analysis extends these findings by establishing a temporal link, showing that car crashes are associated with increased COVID-19 rates acutely. Furthermore, we found that this increase in crashes is independent of Long COVID rates, focusing on acute infections as the primary driver. Interestingly, vaccination does not appear to confer a protective effect against crash risk, contradicting prior studies associating vaccine hesitancy with elevated crash risk [39]. States with extended mask mandates, like Connecticut, experienced prolonged periods of reduced traffic crash rates, whereas our inability to establish statistical significance in Iowa and Washington likely stems from data reporting issues and differences in pandemic-related behavioral changes, such as work-from-home arrangements in Washington and a lack of mitigation efforts in Iowa.

Further, we chose not to include gas prices as a variable, as previous data has demonstrated that gas demand is inelastic, meaning driving choices do not immediately reflect pricing, and this variable was deemed irrelevant to our focus on acute COVID-19. Additionally, over 10% of US vehicles currently on the road are powered by electricity reducing the relevance of traditional fuel price metrics [74,75].

Our observed odds ratio 1.25 [1.23-1.26] is comparable to that associated with a blood alcohol concentration (BAC) of 0.08%, the legal threshold for driving under the influence (DUI) in many states. Comparatively, states such as Utah, which set lower BAC limits of 0.05%, show similar crash risk odds ratios, underlining the substantial impact of acute COVID-19 on driving safety [76]. This finding is also consistent with odds ratios linked to various problematic driving behaviors, such as habitual speeding or running red lights—activities that are illegal and heavily enforced due to their significant risk profiles drawing the ire of public [77]. Although this study examined aggregate data cannot definitively determine the causality of COVID’s effects on the central nervous system (CNS) & car crash frequency, the hypothesis is defensible both mechanistically and statistically.

Our analysis faced several limitations, including the rising prevalence of uninsured drivers, which may contribute to crash underreporting, and the inability to directly confirm acute COVID-19 infections in individuals involved in these crashes, given the population-level nature of the data. Despite these limitations, our findings provide substantial support for the hypothesis that acute COVID-19 contributes to increased car crash risk.

Some prior studies have reported decreases in car crashes frequencies concurrent with rising COVID-19 case rates. However, these studies were conducted in countries such as Japan and Greece, where stringent mitigation measures significantly restricted population mobility, leading to immediate reductions in traffic volume. Importantly, not all studies demonstrated corresponding decreases in fatalities beyond reductions in crash frequency [78,79]. While these studies addressed changes in crash occurrences alongside fatalities and injuries, our analysis highlights the distinct role of acute COVID-19 in contributing to the risk of car crashes. This distinction is critical, as crash severity involves unique risk factors that differ from those influencing crash frequencies alone. For example, prior research shows that population density and traffic density as inversely correlated risk factors for crashes and fatalities [80,81].

Previous studies on exploration of crash heterogeneity further support the importance of distinguishing between outcomes such as crash frequency and severity. The causal mechanisms underlying crashes of varying severity differ significantly, and generalizing across these categories can lead to erroneous conclusions, highlighting the need for targeted analysis [82]. Ultimately, this perspective strengthens our hypothesis: in settings without restrictive mobility measures, the persistence of crashes suggests that acute COVID-19 may exacerbate risk through mechanisms such as impaired cognition or judgment.

To further elucidate the implications of COVID-19 sequelae on car crashes, additional research—such as case-control or prospective cohort studies—is urgently needed. This is particularly critical given the impacts of COVID-19 on the CNS, especially its effects on cognition, which may lead to judgment errors in high-stakes environments, such as flight decks or nuclear energy plants, with potentially catastrophic consequences.

Conclusions

With the COVID-19 Public Health Emergency (PHE) expiring on May 11, 2023, society has primarily suspended protection against COVID-19. In light of lack of mitigations surrounding COVID-19 spread and the failure of the vaccination-only public health approach that has focused mainly on acute hospitalizations and deaths, further research is urgently needed into Long COVID as well as treatments to help manage the sequelae of an Acute Covid infection.

Legislatures and public health experts should not only view COVID-19 in the sense of acute mortality and morbidity. As brief neuropsychological tests are predictive of Long COVID and validated for driving risk, agencies responsible for driving licenses should implement a short questionnaire at license renewal inquiring about Long COVID/COVID and refer applicants to neuropsychological testing as needed. Perhaps even asking if drivers have had ongoing taste and smell disturbances post-COVID might link applicants with ongoing neurological sequelae of COVID [8385].

Finally, clinicians, particularly those dealing with Long Covid patients in the cognitive setting, such as neurologists, must remember their obligation to report patients who potentially constitute medically impaired drivers. Such patients may include those with COVID-19 or those who suffer from the after-effects. Indeed, clinicians, particularly primary care practitioners, should contemplate warning patients with COVID-19 that they should minimize driving and report back if they feel any cognitive sequelae.

Supporting information

S1 Data. Dataset underlying the main analysis with tabs separating data for differing states.

(XLSX)

pgph.0004420.s001.xlsx (925.2KB, xlsx)
S2 Data. Wastewater data including three tabs: percentage subsets of wastewater metrics, concentration data, and a master list of facilities, changes in facility names, primarily within the Verily-sourced wastewater data, are noted.

(XLSX)

pgph.0004420.s002.xlsx (82.8MB, xlsx)

Acknowledgments

I would like to thank Kaitlyn Bruneau, LCSW with her assistance in data collection as well as Sara Anne Willette in her assistance with raw wastewater data collection and analysis.

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

The author received no specific funding for this work.

References

  • 1.Hoerger M. U.S. SARS-CoV-2 wastewater levels, COVID-19 case estimates, and 4-week forecast: Report for March 11, 2024. Pandemic Mitigation Collaborative [Internet]. 2024; (March 11 2024). Available from: https://www.pmc19.com/data/PMC_Report_Mar11_2024.pdf [Google Scholar]
  • 2.Sedgley R, Winer-Jones J, Bonafede M. Long COVID Incidence in a Large US Ambulatory Electronic Health Record System. Am J Epidemiol. 2023;192(8):1350–7. doi: 10.1093/aje/kwad095 [DOI] [PubMed] [Google Scholar]
  • 3.Wentz E, Ni Z, Yenokyan K, Vergara C, Pahwa J, Kammerling T, et al. Cohort profile: the Johns Hopkins COVID Long Study (JHCLS), a United States Nationwide Prospective Cohort Study. medRxiv. 2024:2024.04.25.24306387. doi: 10.1101/2024.04.25.24306387 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Seeßle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clin Infect Dis. 2022;74(7):1191–8. doi: 10.1093/cid/ciab611 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022;28(11):2398–405. doi: 10.1038/s41591-022-02051-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. 2023;2(1):e000385. doi: 10.1136/bmjmed-2022-000385 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Doll MK, Waghmare A, Heit A, Levenson Shakoor B, Kimball LE, Ozbek N, et al. Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves. JAMA Netw Open. 2023;6(2):e231181. doi: 10.1001/jamanetworkopen.2023.1181 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Marjenberg Z, Leng S, Tascini C, Garg M, Misso K, El Guerche Seblain C, et al. Risk of long COVID main symptoms after SARS-CoV-2 infection: a systematic review and meta-analysis. Sci Rep. 2023;13(1):15332. doi: 10.1038/s41598-023-42321-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–46. doi: 10.1038/s41579-022-00846-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Mina Y, Enose-Akahata Y, Hammoud DA, Videckis AJ, Narpala SR, O’Connell SE, et al. Deep Phenotyping of Neurologic Postacute Sequelae of SARS-CoV-2 Infection. Neurol Neuroimmunol Neuroinflamm. 2023;10(4):e200097. doi: 10.1212/NXI.0000000000200097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Braga J, Lepra M, Kish SJ, Rusjan PM, Nasser Z, Verhoeff N, et al. Neuroinflammation After COVID-19 With Persistent Depressive and Cognitive Symptoms. JAMA Psychiatry. 2023;80(8):787–95. doi: 10.1001/jamapsychiatry.2023.1321 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fernández-Castañeda A, Lu P, Geraghty AC, Song E, Lee M-H, Wood J, et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell. 2022;185(14):2452–2468.e16. doi: 10.1016/j.cell.2022.06.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021;48(9):2823–33. doi: 10.1007/s00259-021-05215-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Partiot E, Hirschler A, Colomb S, Lutz W, Claeys T, Delalande F, et al. Brain exposure to SARS-CoV-2 virions perturbs synaptic homeostasis. Nat Microbiol. 2024;9(5):1189–206. doi: 10.1038/s41564-024-01657-2 [DOI] [PubMed] [Google Scholar]
  • 15.Lee MH, Perl DP, Steiner J, Pasternack N, Li W, Maric D, et al. Neurovascular injury with complement activation and inflammation in COVID-19. Brain. 2022;145(7):2555–68. doi: 10.1093/brain/awac151 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Stein JA, Kaes M, Smola S, Schulz-Schaeffer WJ. Neuropathology in COVID-19 autopsies is defined by microglial activation and lesions of the white matter with emphasis in cerebellar and brain stem areas. Front Neurol. 2023;14:1229641. doi: 10.3389/fneur.2023.1229641 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Baker J, Incognito AV, Wilson RJA, Raj SR. Syncope and silent hypoxemia in COVID-19: Implications for the autonomic field. Auton Neurosci. 2021;235:102842. doi: 10.1016/j.autneu.2021.102842 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697–707. doi: 10.1038/s41586-022-04569-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ziff OJ, Ashton NJ, Mehta PR, Brown R, Athauda D, Heaney J, et al. Amyloid processing in COVID-19-associated neurological syndromes. J Neurochem. 2022;161(2):146–57. doi: 10.1111/jnc.15585 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Proal AD, VanElzakker MB, Aleman S, Bach K, Boribong BP, Buggert M, et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol. 2023;24(10):1616–27. doi: 10.1038/s41590-023-01601-2 [DOI] [PubMed] [Google Scholar]
  • 21.Yin K, Peluso MJ, Luo X, Thomas R, Shin M-G, Neidleman J, et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat Immunol. 2024;25(2):218–25. doi: 10.1038/s41590-023-01724-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Gutman EG, Salvio AL, Fernandes RA, Duarte LA, Raposo-Vedovi JV, Alcaraz HF, et al. Long COVID: plasma levels of neurofilament light chain in mild COVID-19 patients with neurocognitive symptoms. Mol Psychiatry. 2024;29(10):3106–16. doi: 10.1038/s41380-024-02554-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Marottoli RA, Cooney LM Jr, Wagner R, Doucette J, Tinetti ME. Predictors of automobile crashes and moving violations among elderly drivers. Ann Intern Med. 1994;121(11):842–6. doi: 10.7326/0003-4819-121-11-199412010-00003 [DOI] [PubMed] [Google Scholar]
  • 24.Stutts JC, Stewart JR, Martell C. Cognitive test performance and crash risk in an older driver population. Accid Anal Prev. 1998;30(3):337–46. doi: 10.1016/s0001-4575(97)00108-5 [DOI] [PubMed] [Google Scholar]
  • 25.Curry AE, Yerys BE, Metzger KB, Carey ME, Power TJ. Traffic Crashes, Violations, and Suspensions Among Young Drivers With ADHD. Pediatrics. 2019;143(6):e20182305. doi: 10.1542/peds.2018-2305 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Grabowski DC, Campbell CM, Morrisey MA. Elderly licensure laws and motor vehicle fatalities. JAMA. 2004;291(23):2840–6. doi: 10.1001/jama.291.23.2840 [DOI] [PubMed] [Google Scholar]
  • 27.Krumholz A, Fisher RS, Lesser RP, Hauser WA. Driving and epilepsy. A review and reappraisal. JAMA. 1991;265(5):622–6. doi: 10.1001/jama.1991.03460050076024 [DOI] [PubMed] [Google Scholar]
  • 28.Dong X, Xie K, Yang H. How did COVID-19 impact driving behaviors and crash Severity? A multigroup structural equation modeling. Accid Anal Prev. 2022;172:106687. doi: 10.1016/j.aap.2022.106687 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.de Paula JJ, Paiva RERP, Souza-Silva NG, Rosa DV, Duran FL de S, Coimbra RS, et al. Selective visuoconstructional impairment following mild COVID-19 with inflammatory and neuroimaging correlation findings. Mol Psychiatry. 2023;28(2):553–63. doi: 10.1038/s41380-022-01632-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Hu Y, Ye B, Ma T, Feng Z, Chen X, Huang D, et al. Exposure to COVID-19 and aggression: the mediating role of anxiety and the moderating role of rumination. Curr Psychol. 2023:1–9. doi: 10.1007/s12144-023-04503-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Monfort SS, Cicchino JB, Patton D. Weekday bicycle traffic and crash rates during the COVID-19 pandemic. J Transp Health. 2021;23:101289. doi: 10.1016/j.jth.2021.101289 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Brodeur A, Cook N, Wright T. On the effects of COVID-19 safer-at-home policies on social distancing, car crashes and pollution. J Environ Econ Manage. 2021;106:102427. doi: 10.1016/j.jeem.2021.102427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Lee J, Liu H, Abdel-Aty M. Changes in traffic crash patterns: Before and after the outbreak of COVID-19 in Florida. Accid Anal Prev. 2023;190:107187. doi: 10.1016/j.aap.2023.107187 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Adanu EK, Brown D, Jones S, Parrish A. How did the COVID-19 pandemic affect road crashes and crash outcomes in Alabama?. Accid Anal Prev. 2021;163:106428. doi: 10.1016/j.aap.2021.106428 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Stiles J, Kar A, Lee J, Miller HJ. Lower Volumes, Higher Speeds: Changes to Crash Type, Timing, and Severity on Urban Roads from COVID-19 Stay-at-Home Policies. Transp Res Rec. 2023;2677(4):15–27. doi: 10.1177/03611981211044454 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Kabiri N, Abbasi A, Pashazadeh F, Hajebrahimi S, Soleimanpour H. The Impact of The COVID-19 Pandemic on Hospital Admissions Due to Road Traffic Crashes; a Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2023;12(1):e12. doi: 10.22037/aaem.v12i1.2157 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Patwary AL, Khattak AJ. Crash harm before and during the COVID-19 pandemic: Evidence for spatial heterogeneity in Tennessee. Accid Anal Prev. 2023;183:106988. doi: 10.1016/j.aap.2023.106988 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hughes JE, Kaffine D, Kaffine L. Decline in Traffic Congestion Increased Crash Severity in the Wake of COVID-19. Transp Res Rec. 2023;2677(4):892–903. doi: 10.1177/03611981221103239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Redelmeier DA, Wang J, Thiruchelvam D. COVID Vaccine Hesitancy and Risk of a Traffic Crash. Am J Med. 2023;136(2):153–162.e5. doi: 10.1016/j.amjmed.2022.11.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Doucette ML, Tucker A, Auguste ME, Watkins A, Green C, Pereira FE, et al. Initial impact of COVID-19’s stay-at-home order on motor vehicle traffic and crash patterns in Connecticut: an interrupted time series analysis. Inj Prev. 2021;27(1):3–9. doi: 10.1136/injuryprev-2020-043945 [DOI] [PubMed] [Google Scholar]
  • 41.Egeli A, Adıgüzel S, Kapıcı Y, Güc B, Yetkin Tekin A, Tekin A. Risk-Taking Behavior in Recovered COVID-19 Patients. Psychiatr Danub. 2021;33(1):107–13. doi: 10.24869/psyd.2021.107 [DOI] [PubMed] [Google Scholar]
  • 42.Thomasson M, Voruz P, Cionca A, Jacot de Alcântara I, Nuber-Champier A, Allali G, et al. Markers of limbic system damage following SARS-CoV-2 infection. Brain Commun. 2023;5(4):fcad177. doi: 10.1093/braincomms/fcad177 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Lukiw WJ, Pogue A, Hill JM. SARS-CoV-2 Infectivity and Neurological Targets in the Brain. Cell Mol Neurobiol. 2022;42(1):217–24. doi: 10.1007/s10571-020-00947-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Taskiran-Sag A, Yazgi H. Limbic system damage following SARS-CoV2 infection. Brain Commun. 2023;5(6):fcad340. doi: 10.1093/braincomms/fcad340 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Tsai CI, Zeng Y. Risky but alluring: Severe COVID-19 pandemic influence increases risk taking. J Exp Psychol Appl. 2021;27(4):679–94. doi: 10.1037/xap0000380 [DOI] [PubMed] [Google Scholar]
  • 46.Alhajyaseen WKM, Almukdad A, Hussain Q, Almallah M, Al Malki MA, Singaravelu J, et al. Road safety status during COVID-19 pandemic: exploring public and road safety expert’s opinions. Int J Inj Contr Saf Promot. 2022;29(2):135–51. doi: 10.1080/17457300.2021.1962915 [DOI] [PubMed] [Google Scholar]
  • 47.Kabbush O, Almannaa M, Alarifi SA, Alghamdi A. Assessing the Effect of COVID-19 on the Traffic Safety of Intercity and Major Intracity Roads in Saudi Arabia. Arab J Sci Eng. 2023:1–19. doi: 10.1007/s13369-023-07883-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Ehsani JP, Kinnear N. Young driver licensing and COVID-19. Inj Prev. 2021;27(6):574–6. doi: 10.1136/injuryprev-2020-044053 [DOI] [PubMed] [Google Scholar]
  • 49.Vaca FE, Li K. Do the Youngest Drivers Crash the Most?. JAMA Netw Open. 2022;5(4):e228785. doi: 10.1001/jamanetworkopen.2022.8785 [DOI] [PubMed] [Google Scholar]
  • 50.Walshe EA, Romer D, Wyner AJ, Cheng S, Elliott MR, Zhang R, et al. Licensing Examination and Crash Outcomes Postlicensure in Young Drivers. JAMA Netw Open. 2022;5(4):e228780. doi: 10.1001/jamanetworkopen.2022.8780 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Michelaraki E, Sekadakis M, Katrakazas C, Ziakopoulos A, Yannis G. One year of COVID-19: Impacts on safe driving behavior and policy recommendations. J Safety Res. 2023;84:41–60. doi: 10.1016/j.jsr.2022.10.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Alsofayan YM, Alghnam SA, Alkhorisi AM, Almalki HA, Alsaihani MD, Almazroa MA, et al. Epidemiology of Traffic Injuries before, during and 1 Year after the COVID-19 Pandemic Restrictions: National Findings from the Saudi Red Crescent Authority. Saudi J Med Med Sci. 2022;10(2):111–6. doi: 10.4103/sjmms.sjmms_59_22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Kılıç C, Yıldız Mİ, Emekli E, Gülşen G, Alp A. Psychological factors responsible for low adherence to mask-wearing measures during the COVID-19 pandemic. BJPsych Open. 2022;8(6):e203. doi: 10.1192/bjo.2022.603 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Reuter M, Rigó M, Formazin M, Liebers F, Latza U, Castell S, et al. Occupation and SARS-CoV-2 infection risk among 108 960 workers during the first pandemic wave in Germany. Scand J Work Environ Health. 2022;48(6):446–56. doi: 10.5271/sjweh.4037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Zhang M. Estimation of differential occupational risk of COVID-19 by comparing risk factors with case data by occupational group. Am J Ind Med. 2021;64(1):39–47. doi: 10.1002/ajim.23199 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Lin L, Shi F, Li W. Assessing inequality, irregularity, and severity regarding road traffic safety during COVID-19. Sci Rep. 2021;11(1):13147. doi: 10.1038/s41598-021-91392-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Vanlaar WGM, Woods-Fry H, Barrett H, Lyon C, Brown S, Wicklund C, et al. The impact of COVID-19 on road safety in Canada and the United States. Accid Anal Prev. 2021;160:106324. doi: 10.1016/j.aap.2021.106324 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Mungmunpuntipantip R, Wiwanitkit V. The COVID-19 pandemic and traffic accidents. S Afr Med J. 2021;111(3):13227. doi: 10.7196/SAMJ.2021.v111i3.15531 [DOI] [PubMed] [Google Scholar]
  • 59.Atique S, Asim M, El-Menyar A, Mathradikkal S, Hammo A-A, Baykuziyev T, et al. Motorcycle-related crashes before and during the COVID-19 pandemic: A comparative retrospective observational study from the Middle East. Injury. 2024;55(3):111343. doi: 10.1016/j.injury.2024.111343 [DOI] [PubMed] [Google Scholar]
  • 60.Ford ND, Agedew A, Dalton AF, Singleton J, Perrine CG, Saydah S. Notes from the Field: Long COVID Prevalence Among Adults - United States, 2022. MMWR Morb Mortal Wkly Rep. 2024;73(6):135–6. doi: 10.15585/mmwr.mm7306a4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.CTDOT. Connecticut Crash Data Repository (CTCDR) Available from: https://www.ctcrash.uconn.edu/QueryTool2.action [Google Scholar]
  • 62.DOT I. ICAT - Iowa Crash Analysis Tool. Available from: https://icat.iowadot.gov [Google Scholar]
  • 63.FLHSMV. Crash Dashboard. Available from: https://www.flhsmv.gov/traffic-crash-reports/crash-dashboard/ [Google Scholar]
  • 64.GDOT. Georgia Crash Data. Available from: https://gdot.aashtowaresafety.net/crash-data#/ [Google Scholar]
  • 65.MassDOT. IMPACT. Available from: https://apps.impact.dot.state.ma.us/cdp/home [Google Scholar]
  • 66.NHTSA. National Center for Statistics and Analysis (NCSA) Motor Vehicle Traffic Crash Data. Available from: https://cdan.dot.gov/query [Google Scholar]
  • 67.Patrol WS. Collision Analysis Tool Available from: https://fortress.wa.gov/wsp/collisionanalysistool/Query/SearchCriteria [Google Scholar]
  • 68.TxDOT. TxDOT Crash Query Tool. Available from: https://cris.dot.state.tx.us/public/Query/app/home [Google Scholar]
  • 69.Services USDoHH. COVID-19 Vaccinations in the United States,Jurisdiction. Available from: https://catalog.data.gov/dataset/covid-19-vaccinations-in-the-united-statesjurisdiction-07bc5 [Google Scholar]
  • 70.Services USDoHH. COVID Data Tracker. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home [Google Scholar]
  • 71.Parkins MD, Lee BE, Acosta N, Bautista M, Hubert CRJ, Hrudey SE, et al. Wastewater-based surveillance as a tool for public health action: SARS-CoV-2 and beyond. Clin Microbiol Rev. 2024;37(1):e0010322. doi: 10.1128/cmr.00103-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Saber LB, Kennedy SS, Yang Y, Moore KN, Wang Y, Hilton SP, et al. Correlation of SARS-CoV-2 in Wastewater and Individual Testing Results in a Jail, Atlanta, Georgia, USA. Emerg Infect Dis. 2024;30(13):S21–7. doi: 10.3201/eid3013.230775 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Robertson L. Did “long COVID” increase road deaths in the USA?. Inj Prev. 2025;31(1):18–20. doi: 10.1136/ip-2023-045136 [DOI] [PubMed] [Google Scholar]
  • 74.Dwyer M. United States: Electric vehicles and hybrids surpass 16% of total 2023 U.S. light-duty vehicle sales. In: Administration USEI, editor. 2024. [Google Scholar]
  • 75.Eitches E, Crain V. Using gasoline data to explain inelasticity. In: Statistics USBoL, editor. 2016. [Google Scholar]
  • 76.Blomberg RD, Peck RC, Moskowitz H, Burns M, Fiorentino D. The Long Beach/Fort Lauderdale relative risk study. J Safety Res. 2009;40(4):285–92. doi: 10.1016/j.jsr.2009.07.002 [DOI] [PubMed] [Google Scholar]
  • 77.Akhtar S, Aldhafeeri E, Alshammari F, Jafar H, Malhas H, Botras M, et al. A proportional odds model of risk behaviors associated with recurrent road traffic crashes among young adults in Kuwait. BMC Med Res Methodol. 2022;22(1):19. doi: 10.1186/s12874-021-01497-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Sekadakis M, Katrakazas C, Michelaraki E, Kehagia F, Yannis G. Analysis of the impact of COVID-19 on collisions, fatalities and injuries using time series forecasting: The case of Greece. Accid Anal Prev. 2021;162:106391. doi: 10.1016/j.aap.2021.106391 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Shimada R, Kibayashi K. Changes in the number of traffic collisions during the various waves of COVID-19 infection in Japan. PLoS One. 2022;17(12):e0278941. doi: 10.1371/journal.pone.0278941 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Fischer K, Sternfeld I, Melnick DS. Impact of population density on collision rates in a rapidly developing rural, exurban area of Los Angeles County. Inj Prev. 2013;19(2):85–91. doi: 10.1136/injuryprev-2011-040308 [DOI] [PubMed] [Google Scholar]
  • 81.Robertson LS. Daily motor vehicle traffic volume and other risk factors associated with road deaths in U.S. counties. J Safety Res. 2024;90:43–7. doi: 10.1016/j.jsr.2024.06.001 [DOI] [PubMed] [Google Scholar]
  • 82.Knipling RR. Crash Heterogeneity: Implications for Naturalistic Driving Studies and for Understanding Crash Risks. Transportation Research Record: Journal of the Transportation Research Board. 2017;2663(1):117–25. doi: 10.3141/2663-15 [DOI] [Google Scholar]
  • 83.Arbula S, Pisanu E, Bellavita G, Menichelli A, Lunardelli A, Furlanis G, et al. Insights into attention and memory difficulties in post-COVID syndrome using standardized neuropsychological tests and experimental cognitive tasks. Sci Rep. 2024;14(1):4405. doi: 10.1038/s41598-024-54613-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Maffei M, Mazzatenta A, Origlia N. Editorial: Loss of taste and smell in COVID-19 patients: A prognostic tool and a starting point to investigate the action of SARS-CoV-2 in the central nervous system. Front Cell Neurosci. 2023;17:1191227. doi: 10.3389/fncel.2023.1191227 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Sharetts R, Moein ST, Khan R, Doty RL. Long-Term Taste and Smell Outcomes After COVID-19. JAMA Netw Open. 2024;7(4):e247818. doi: 10.1001/jamanetworkopen.2024.7818 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLOS Glob Public Health. doi: 10.1371/journal.pgph.0004420.r002

Decision Letter 0

Steve Zimmerman

26 Jun 2024

PGPH-D-24-01012

Driving under viral impairment: Linking acute SARS-CoV-2 infections to elevated car crash risks

PLOS Global Public Health

Dear Dr. Erdik,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please note that we have only been able to secure a single reviewer to assess your manuscript. We are issuing a decision on your manuscript at this point to prevent further delays in the evaluation of your manuscript. Please be aware that the editor who handles your revised manuscript might find it necessary to invite additional reviewers to assess this work once the revised manuscript is submitted. However, we will aim to proceed on the basis of this single review if possible. 

The comments from the reviewer are below. I agree with the reviewer that a more thorough analysis of the existing literature on the associations between COVID 19 and car crashes is needed (although it is not a requirement that you cite the specific papers mentioned by the reviewer).

I also agree that a lot more methodological details are needed. At present it is not clear what data you used, when and how you obtained it, and what variables were included. Please provide more precise details of the datasets you accessed such that other researchers would be able to reproduce your research. Please also provide whatever data you can as supplementary files (see https://journals.plos.org/globalpublichealth/s/data-availability).

Please also provide details on your raw wastewater data collection and analysis, including sources of sample, lab procedures, and analytic techniques.

Please submit your revised manuscript by Aug 08 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Steve Zimmerman, PhD

PLOS Staff Editor

Journal Requirements:

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does this manuscript meet PLOS Global Public Health’s publication criteria ? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This paper examines the association between COVID-19 and car crashes across U.S. states, correlating with the implemented mitigation strategies, vaccination rates, and long COVID prevalence. The following remarks should be taken into consideration in the revised version of this paper:

The authors should structure a more thorough literature review, extending the existing insights to reflect the extensive research performed since the COVID-19 spread. The focus should be more on the traffic impacts and the origins of traffic crashes, highlighting that the increase in crashes is a combination of behavioral changes and primarily the reduction in traffic volumes. See:

• Adanu, E. K., Brown, D., Jones, S., & Parrish, A. (2021). How did the COVID-19 pandemic affect road crashes and crash outcomes in Alabama?. Accident Analysis & Prevention, 163, 106428.

• Sekadakis, M., Katrakazas, C., Michelaraki, E., Kehagia, F., & Yannis, G. (2021). Analysis of the impact of COVID-19 on collisions, fatalities, and injuries using time series forecasting: The case of Greece. Accident Analysis & Prevention, 162, 106391.

It is significant, based on the literature review, to highlight the innovation of this study. Furthermore, the methodology should be extended to include the databases used, methods employed, and descriptive statistics of the datasets. Additionally, the authors should substantiate why Poisson regression was chosen. The discussion and conclusions should be strengthened in logical flow and discussed more thoroughly.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0004420.r004

Decision Letter 1

Jose Ignacio Nazif-Munoz

22 Jan 2025

PGPH-D-24-01012R1

Driving under viral impairment: Linking acute SARS-CoV-2 infections to elevated car crash risks

PLOS Global Public Health

Dear Dr. Baran Erdik,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address the following observations to enhance the clarity, consistency, and rigor of your work:

Abstract and Methods Consistency:

  • In the abstract, the analysis is described as covering the period from 2020 to 2023 (lines 19–20, page 2). However, in the Methods section (page 8, line 143), data collection is stated to have occurred between March and May 2024. Please clarify the exact data period used in the study.

Materials and Methods:

  • Specify the exact number of states included in the analysis instead of referring to “several” states.

  • Elaborate on the extent to which crude and refined wastewater metrics were utilized.

  • Include explicit references for the sources of information described in the Methods section to ensure transparency.

Results Section:

  • Ensure there is no repetition in the text. For example, the wording in lines 181–185 (page 10) is repeated.

  • Correct the duplication of Table 2 to avoid confusion.

Terminology:

  • Avoid using the term “accidents” and consistently use “crashes” throughout the manuscript.

Methods Section:

  • Provide a detailed description of the Poisson model used, including whether fixed or random effects were applied, and justify the choice in light of state-level analysis.

  • Describe how overdispersion was assessed and explain why a Negative Binomial model was not used.

  • Move the description of the heat map from the Results section to the Methods section and clarify how it was constructed and used to identify variables for the models.

  • Revise the equation to properly include the log of the population as an offset, and ensure the outcome is clearly described as a log-transformed variable.

  • State the software used to perform the analyses.

Discussion Section:

  • Revise the statement in line 269 (page 15) to avoid conflating fatalities and crashes, as these are distinct outcomes. Ensure the discussion aligns with the specific outcome being analyzed.

References:

Include and properly cite the following reference, which was mentioned in your discussion:

R.R. Knipling, “Crash Heterogeneity: Implications for Naturalistic Driving Studies and for Understanding Crash Risks,” Transp. Res. Rec., 2663 (2017), pp. 117-125, 10.3141/2663-15.

Please submit your revised manuscript by February8th 2025. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Jose Ignacio Nazif-Munoz, Ph.D.

Academic Editor

PLOS Global Public Health

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Does this manuscript meet PLOS Global Public Health’s publication criteria ? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have thoroughly revised the manuscript in response to the reviewer's comments. The revised version has been improved and now meets the journal's publication requirements.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0004420.r006

Decision Letter 2

Jose Ignacio Nazif-Munoz

25 Feb 2025

Driving under viral impairment: Linking acute SARS-CoV-2 infections to elevated car crash risks

PGPH-D-24-01012R2

Dear Dr. Baran Erdik,

We are pleased to inform you that your manuscript 'Driving under viral impairment: Linking acute SARS-CoV-2 infections to elevated car crash risks' has been provisionally accepted for publication in PLOS Global Public Health.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Global Public Health.

Best regards,

Jose Ignacio Nazif-Munoz, Ph.D.

Academic Editor

PLOS Global Public Health

***********************************************************

Reviewer Comments (if any, and for reference):

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Data. Dataset underlying the main analysis with tabs separating data for differing states.

    (XLSX)

    pgph.0004420.s001.xlsx (925.2KB, xlsx)
    S2 Data. Wastewater data including three tabs: percentage subsets of wastewater metrics, concentration data, and a master list of facilities, changes in facility names, primarily within the Verily-sourced wastewater data, are noted.

    (XLSX)

    pgph.0004420.s002.xlsx (82.8MB, xlsx)
    Attachment

    Submitted filename: response to reviewers.pdf

    pgph.0004420.s003.pdf (66.1KB, pdf)
    Attachment

    Submitted filename: response to reviewers_r2.pdf

    pgph.0004420.s004.pdf (58.6KB, pdf)

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.


    Articles from PLOS Global Public Health are provided here courtesy of PLOS

    RESOURCES